THBS1 and non-small cell lung carcinoma: Our studies revealed that the MTR administration of OralGem in an NSCLC xenografted mouse model restrained neoangiogenesis by altering two main mechanisms: increasing the expression of the anti-angiogenic factor TSP-1 and decreasing the pro-angiogenic factor VEGFA.